BackAtossa Therapeutics Overview

Atossa Therapeutics Total Current Liabilities

Track Atossa Therapeutics's total current liabilities ($7.5M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$7.46M
37.46% YoYΔ $2.03M vs prior year quarter

Peer average

Loading

Atossa Therapeutics Total Current Liabilities History

Loading

Atossa Therapeutics vs. peers: Total Current Liabilities Comparison

Loading

Atossa Therapeutics Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Atossa Therapeutics (ATOS) FAQ

Atossa Therapeutics posts a total current liabilities of $7.5M as of March 2026. That compares with $5.4M in the prior-year period — up 37.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Atossa Therapeutics's total current liabilities was $5.4M. The latest reading is $7.5M — a 37.5% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Total Current Liabilities is one piece of Atossa Therapeutics's financial statement story. At $7.5M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ATOS's total current liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Atossa Therapeutics's other metric pages and overview cover the third.

Judging Atossa Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total current liabilities easier to interpret. Start with $7.5M here, then scan peer and history charts to see if the gap is persistent.